Efficacy and Safety of Infliximab in Older Inflammatory Bowel Disease Patients

Authors

Christina Cress Lindenmeyer, MD, Thomas Jefferson University HospitalsFollow
Stephanie M. Moleski, MD, Thomas Jefferson University HospitalFollow
Maureen P. Whitsett, MEd., Thomas Jefferson University
Patricia L. Kozuch, MD, Thomas Jefferson University HospitalFollow

Document Type

Poster

Publication Date

10-13-2013

Comments

Presented at: the American College of Gastroenterology Annual Meeting in San Diego.

Abstract

Background:

The limited data regarding treatment of inflammatory bowel disease (IBD) with anti-tumor necrosis factor antibodies in older patients suggest equal efficacy but higher morbidity and mortality compared to younger patients. This retrospective case control study aims to clarify the efficacy and safety of infliximab (IFX) in older IBD patients.

Recommended Citation

Lindenmeyer, MD, Christina Cress; Moleski, MD, Stephanie M.; Whitsett, MEd., Maureen P.; and Kozuch, MD, Patricia L., "Efficacy and Safety of Infliximab in Older Inflammatory Bowel Disease Patients" (2013). Division of Gastroenterology and Hepatology Faculty Papers. Paper 21.
https://jdc.jefferson.edu/gastro_hepfp/21